Rheumatoid Arthritis — Clinical Documentation Guide (2026)

🔍 Definition

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disorder characterized by symmetric polyarticular synovitis leading to progressive joint destruction, functional disability, and significant extra-articular manifestations. The immune system mistakenly attacks the synovial membrane lining the joints, producing inflammatory cytokines — primarily tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) — that drive cartilage erosion, bone damage, and systemic organ involvement. According to the CDC, RA affects approximately 1.3 million adults in the United States, with women diagnosed two to three times more frequently than men. Peak onset occurs between ages 30–60, though the condition can present at any age including childhood (juvenile RA).

For ICD-10-CM FY2026 purposes, RA is classified primarily by serologic status: seropositive (rheumatoid factor [RF]-positive, category M05) versus seronegative (RF-negative, category M06), with juvenile forms under M08. The presence or absence of rheumatoid factor has important implications for code selection, risk adjustment scoring, and CDI query priority. Anti-citrullinated protein antibody (anti-CCP/ACPA) positivity — captured separately under M05.A (FY2026) — indicates a more aggressive disease course and warrants distinct documentation.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

RA presents with a characteristic constellation of articular and systemic features. Coders and CDI specialists should be alert to documentation of these findings as they support medical necessity, code specificity, and risk stratification. Per the American College of Rheumatology (ACR):

• Morning stiffness lasting >60 minutes — a hallmark feature; duration correlates with disease activity
• Symmetric joint swelling — metacarpophalangeal (MCP), proximal interphalangeal (PIP), wrist, knee, ankle joints most commonly affected; DIP joints typically spared (distinguishing from osteoarthritis)
• Joint tenderness and warmth on examination; boggy synovial thickening
• Fatigue, malaise, low-grade fever — systemic constitutional symptoms
• Joint deformities (late disease): swan-neck deformity, boutonnière deformity, ulnar deviation, Z-thumb
• Subcutaneous rheumatoid nodules — firm, non-tender, over pressure points (olecranon, sacrum, fingers); seen in ~20% of RF+ patients
• Pulmonary involvement: interstitial lung disease (ILD), pleural effusion, pulmonary nodules, bronchiolitis obliterans
• Cardiac involvement: pericarditis, myocarditis, accelerated atherosclerosis, conduction abnormalities
• Ocular involvement: scleritis, episcleritis, keratoconjunctivitis sicca (secondary Sjögren’s), uveitis (H20.x — code separately)
• Vasculitis: digital infarcts, skin ulceration, mononeuritis multiplex, mesenteric ischemia (severe/rare)
• Felty’s syndrome triad: RA + splenomegaly + neutropenia — associated with M05.0x codes
• Anemia of chronic disease; thrombocytosis during flares
• Elevated inflammatory markers: ESR, CRP, positive RF (IgM), anti-CCP antibodies

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

The following documentation elements are essential for accurate RA code selection in FY2026. Coders should review the entire record — problem list, medication list, rheumatology notes, lab results, and imaging reports — for supporting evidence.

🦴 Anatomy & Pathophysiology

RA primarily targets the synovial joint, affecting the synovial membrane (synovium) that lines joint cavities. The pathophysiologic cascade involves:

1. Initiation: Antigen presentation by HLA-DR4/DR1 MHC class II molecules activates CD4+ T-helper cells (Th1 and Th17 subtypes). Citrullinated peptides — generated by peptidylarginine deiminase (PAD) enzyme — trigger anti-CCP antibody production in genetically susceptible individuals.
2. Synovial inflammation: B cells, plasma cells, and macrophages infiltrate the synovium, producing rheumatoid factor (anti-IgG antibody) and pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, IL-17. The synovium transforms into invasive granulation tissue called pannus.
3. Joint destruction: Pannus erodes articular cartilage (via matrix metalloproteinases) and subchondral bone (via RANKL-stimulated osteoclasts), leading to marginal erosions visible on X-ray and MRI. Progressive joint space narrowing, subluxation, and ankylosis occur in untreated or undertreated disease.
4. Systemic inflammation: Circulating cytokines (especially IL-6) drive systemic features — anemia of chronic disease, hepatic acute-phase protein production (elevated CRP/ESR), accelerated cardiovascular disease risk, and extra-articular organ involvement.
5. Sites of extra-articular involvement:
   • Lungs: Pleural effusion, interstitial lung disease (UIP, NSIP patterns), pulmonary nodules, bronchiectasis — documented as RA lung disease, coded M05.1x per ICD-10-CM FY2026 tabular
   • Cardiovascular: Pericarditis, myocarditis, accelerated coronary artery disease — coded M05.3x for rheumatoid heart disease
   • Vasculature: Rheumatoid vasculitis affects medium/small vessels — M05.2x; additional code I77.6 may be warranted per provider documentation
   • Neuromuscular: Peripheral neuropathy (M05.5x), myopathy with proximal muscle weakness (M05.4x)
   • Felty’s syndrome: Splenomegaly with neutropenia in severe long-standing RF+ RA — M05.0x

💊 Medication Impact / Treatment

Pharmacologic management of RA is a critical documentation element for coders. The treatment pathway follows a structured escalation approach per ACR 2021 RA Treatment Guidelines:

Conventional Synthetic DMARDs (csDMARDs)

• Methotrexate (MTX) — anchor therapy; first-line for most patients; weekly dosing; requires folic acid supplementation. Long-term use: Z79.899
• Hydroxychloroquine (Plaquenil) — mild-moderate disease; requires annual ophthalmologic monitoring
• Sulfasalazine — second-line csDMARD; often used in combination
• Leflunomide (Arava) — alternative to MTX; teratogenic; active metabolite monitoring required

Biologic DMARDs (bDMARDs) — TNF Inhibitors

• Adalimumab (Humira) — J0135; subcutaneous; biosimilars: Q5140–Q5145 (adalimumab-fkjp, -aaty, -ryvk, -adbm, etc.); prior authorization required
• Etanercept (Enbrel) — J1438; subcutaneous; TNF receptor fusion protein
• Infliximab (Remicade) — J1745; IV infusion; biosimilars: Q5103 (Inflectra/infliximab-dyyb), Q5104 (Renflexis/infliximab-abda), Q5121 (Avsola/infliximab-axxq)
• Golimumab IV (Simponi Aria) — J1602; IV formulation only for RA (subcutaneous golimumab uses different J-code)
• Certolizumab pegol (Cimzia) — J0718; subcutaneous

Biologic DMARDs — Non-TNF Mechanisms

• Abatacept (Orencia) — J0129; T-cell costimulation blocker; IV infusion
• Tocilizumab (Actemra) — J3262; IL-6 receptor blocker; IV or subcutaneous
• Rituximab (Rituxan) — J9312; CD20 B-cell depleting agent; used in RF+ or anti-CCP+ patients; IV infusion
• Sarilumab (Kevzara) — J2182; IL-6 receptor blocker; subcutaneous

Targeted Synthetic DMARDs (tsDMARDs) — JAK Inhibitors

Oral JAK inhibitors are NOT administered via infusion and do NOT have J-codes. Use Z79.899 for long-term use documentation. Unclassified oral agents may use J3490 in exceptional circumstances per payer policy:

• Tofacitinib (Xeljanz) — oral JAK1/JAK3 inhibitor; FDA black box warning for cardiovascular events and malignancy
• Baricitinib (Olumiant) — oral JAK1/JAK2 inhibitor
• Upadacitinib (Rinvoq) — oral selective JAK1 inhibitor
• Filgotinib (Jyseleca) — selective JAK1 inhibitor (EU-approved)

Adjunctive Therapies

• NSAIDs (naproxen, ibuprofen, celecoxib) — symptom relief, not disease-modifying
• Corticosteroids (prednisone, methylprednisolone) — bridge therapy, disease flares, intra-articular injection (CPT 20610/20611)
• Intra-articular corticosteroid injections — corticosteroid ± local anesthetic; CPT 20600–20611 based on joint size

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The following guidelines govern RA code selection under the ICD-10-CM FY2026 Official Guidelines for Coding and Reporting (effective October 1, 2025):

Sequencing & Combination Codes

• Combination codes: M05.1x through M05.6x are combination codes that capture both the seropositive RA AND the associated systemic manifestation in a single code. Do not separately code the manifestation (e.g., lung disease, vasculitis) when the combination code is available. However, additional codes may be assigned for specific complications not captured in the combination code (e.g., H20.x for uveitis; I77.6 for vasculitis if explicitly documented).
• Sequencing: When RA is the reason for the encounter, sequence the M05/M06/M08 code as the principal or first-listed diagnosis. When the encounter is for a manifestation (e.g., infusion of biologic), sequence the RA code first, followed by Z79.899.
• Additional manifestation codes: For pulmonary involvement beyond the M05.1x combination code (e.g., RA with ILD causing respiratory failure), code additionally per guideline instruction. J99 (Respiratory disorders in diseases classified elsewhere) may apply when provider links the pulmonary condition to RA and the M05.1x combination code does not fully capture severity.

Laterality and Site Specificity

• 5th character specifies the anatomical site: 0=unspecified, 1=shoulder, 2=elbow, 3=wrist, 4=hand, 5=hip, 6=knee, 7=ankle and foot, 8=other/vertebrae, 9=multiple sites, A=other specified (FY2026 expansion)
• 6th character specifies laterality for paired structures: 1=right, 2=left, 9=unspecified. Use bilateral coding only when both joints are specifically documented.
• When multiple joints are involved, code the most severe or the primary joint causing the encounter; M05.xx9 or M06.xx9 (multiple sites) is appropriate when the provider documents multiple joint involvement without singling out one dominant joint.

Remission Coding

• RA in remission should still be coded if it requires or affects patient care, treatment, or management. According to Ochsner Health Network CDI guidance, RA is a chronic incurable condition — code even in remission if ongoing medication management is present.
• Do not use Z87.x (personal history) for active RA under ongoing treatment, even if described as “in remission.” Personal history codes are reserved for resolved conditions with no current treatment.

Juvenile RA (M08)

• M08.xx codes apply to arthritis onset before age 16. The site/laterality structure parallels M05/M06.
• M08.1 (Juvenile ankylosing spondylitis) is distinct from adult ankylosing spondylitis (M45) — use M08.1 when onset is in childhood.
• M08.2x (Juvenile RA with systemic onset = systemic JIA/Still’s) differs from M06.1 (Adult-onset Still’s disease).

Excludes Notes

• M05/M06 Excludes1: Rheumatic fever (I00) — RA and rheumatic fever are entirely different conditions; never code both from the same M05/M06 encounter
• M05/M06 Excludes1: Juvenile rheumatoid arthritis (M08.x) — juvenile forms must use M08, not M05/M06
• M05/M06 Excludes1: Rheumatoid arthritis of the spine (M45.x) — axial spondyloarthritis of the spine codes to M45

🔢 ICD-10-CM Code Set (FY2026)

The following tables present the FY2026 ICD-10-CM code sets applicable to RA encounters, per the CMS/NCHS ICD-10-CM FY2026 tabular list.

M05 — Rheumatoid Arthritis with Rheumatoid Factor (Seropositive RA)

M06 — Other Rheumatoid Arthritis (Seronegative / Other)

M08 — Juvenile Arthritis

Additional / Secondary Codes

🔎 Indexing

The following alphabetic index entries guide code lookup in the ICD-10-CM FY2026 Alphabetic Index:

🏥 CPT (2026)

CPT codes for RA encounters cover office/outpatient evaluation and management, joint procedures, and biologic infusion services per the AMA CPT 2026 Professional Edition.

🧾 HCPCS (2026)

The following HCPCS Level II codes apply to biologic therapies administered in outpatient infusion settings for RA. Per CMS HCPCS 2026, J-codes are used for drugs administered by injection or infusion; oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib) are NOT covered by J-codes.

📚 AHA Coding Clinic (Recent Guidance)

The following AHA Coding Clinic for ICD-10-CM/PCS guidance is relevant to RA coding. Coders should access the current subscription database for complete Q&A text.

💰 HCC / Risk Adjustment (v28)

Rheumatoid arthritis maps to HCC 40: Rheumatoid Arthritis and Inflammatory Connective Tissue Disease under the CMS-HCC Model V28, which is fully operative for payment year 2026 (100% implementation as of January 1, 2026 per CMS V28 transition guidance).

HCC 40 Mapping

HCC 40 RAF Weights (CMS-HCC V28)

Source: CMS Revised CMS-HCC Model Relative Factor Tables (V28)

Risk Adjustment Documentation Pearls

• Annual documentation required: HCC 40 must be documented, coded, and submitted every calendar year. Prior-year diagnoses do not carry forward under risk adjustment rules.
• M05 vs. M06 distinction matters: Both map to HCC 40, but seropositive RA (M05) typically reflects higher disease burden and treatment complexity. CDI should ensure serologic status is documented annually.
• V28 is fully operative in 2026: No blending with V24 for payment year 2026. All 115 V28 HCCs apply; conditions that mapped only to V24 HCCs but not V28 HCCs will not count toward risk scores.
• Proposed 2027 reduction: CMS’s proposed 2027 Advance Notice projects a -17.3% coefficient change for Rheumatoid Arthritis under the next model iteration, per RAAPID analysis. Plans should be aware of potential downstream RAF impact.
• Systemic involvement codes: M05.1x–M05.6x (systemic manifestations) all map to HCC 40 — the same HCC as M05.7x/M05.9. While the HCC coefficient does not increase for systemic involvement in V28 (unlike V24), documenting systemic manifestations remains clinically important for audit defense and comorbidity capture (e.g., lung disease → CLD HCC; vasculitis → vascular HCC).

✍️ CDI Query Templates

The following query templates follow ACDIS and AHIMA compliant format: non-leading, multiple-choice, clinically grounded, with “other” and “unable to determine” options.

🧑‍⚕️ Treatments (Clinical)

Comprehensive RA treatment follows a treat-to-target (T2T) strategy per ACR RA Treatment Guidelines (2021, updated), aiming for clinical remission (DAS28 <2.6, CDAI ≤2.8) or low disease activity as the primary goal.

Pharmacologic Treatment Ladder

1. Step 1 — Conventional DMARDs: Methotrexate (MTX) is the cornerstone first-line therapy; hydroxychloroquine, sulfasalazine, and leflunomide as alternatives or combination partners (triple therapy: MTX + HCQ + SSZ)
2. Step 2 — Biologic DMARDs (after inadequate csDMARD response): Add TNF inhibitor (adalimumab, etanercept, infliximab, certolizumab, golimumab) or non-TNF biologic (abatacept, tocilizumab, rituximab for RF+/anti-CCP+ patients)
3. Step 3 — JAK Inhibitors: Tofacitinib, baricitinib, or upadacitinib after biologic DMARD failure or as alternative based on patient preferences and risk profile; FDA black box warnings for increased risk of thrombosis, malignancy, and cardiovascular events
4. Corticosteroids: Short-term bridging therapy during DMARD initiation or disease flares; intra-articular corticosteroid injections (CPT 20610) for persistent single-joint flares

Non-Pharmacologic Interventions

• Physical and occupational therapy: Joint protection techniques, range-of-motion exercises, adaptive devices
• Patient education and self-management: Arthritis self-management programs (ASMP); smoking cessation (smoking worsens RF+ RA)
• Orthopedic surgery: Total joint replacement for end-stage destruction (CPT 27447 TKR, 27130 THR); synovectomy; tendon repair
• Occupational/ergonomic modifications: Splinting for wrist and hand involvement; assistive devices
• Cardiovascular risk reduction: RA carries 2× increased cardiovascular mortality risk; aggressive management of traditional risk factors and inflammatory burden

Monitoring

Regular laboratory monitoring per ACR guidelines: CBC, LFTs, creatinine with MTX (every 8–12 weeks); TB/hepatitis screening before biologic initiation; DAS28 or CDAI at each visit for disease activity assessment; annual cardiovascular risk assessment.

🎓 Patient Education / Summary

The following information is intended for use in patient education materials and discharge instructions, written at an accessible reading level:

What is Rheumatoid Arthritis?

Rheumatoid arthritis (RA) is a long-term (chronic) condition where your immune system — the body’s defense system — mistakenly attacks the lining of your joints. This causes pain, swelling, stiffness, and, over time, can damage the joints. RA is different from “wear-and-tear” arthritis (osteoarthritis); it is an autoimmune disease that can also affect organs like your lungs, heart, and eyes. According to the CDC, about 1.3 million Americans live with RA.

Important Facts for Patients

• Morning stiffness that lasts more than one hour is a hallmark symptom — tell your doctor how long stiffness lasts each morning.
• Both sides of your body are usually affected (symmetric), especially small joints of the hands, wrists, and feet.
• Blood tests (rheumatoid factor, anti-CCP antibody, ESR, CRP) help confirm the diagnosis and track disease activity.
• RA is treatable but not currently curable. With the right medications (DMARDs and/or biologics), many people achieve remission — little to no active inflammation.
• Never stop medications without consulting your rheumatologist — even if you feel better. Stopping treatment can cause a flare.
• Smoking worsens RA and makes biologic therapies less effective. Quitting smoking is one of the most important lifestyle changes.
• Vaccines: Discuss vaccinations (flu, pneumococcal, shingles, COVID-19) with your doctor before starting or while on biologic therapy — some live vaccines cannot be given while on certain biologics.

When to Seek Immediate Care

• Sudden severe worsening of joint pain with redness and warmth — could indicate a joint infection (septic arthritis)
• Shortness of breath or chest pain — RA lung or heart involvement; cardiovascular complications
• High fever with joint swelling — possible Felty’s syndrome complication or infection
• Vision changes, eye pain, or redness — possible uveitis or scleritis (ophthalmology consultation needed)

Helpful Resources

• American College of Rheumatology — RA Patient Resources
• CDC — Rheumatoid Arthritis Information
• Arthritis Foundation — Rheumatoid Arthritis

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)